Cargando…

Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry

BACKGROUNDS: Treatment of difficult-to-treat rheumatoid arthritis (D2T RA) is one of the greatest unmet needs in rheumatology. This study aims to find out preferable treatment options for a group of D2T RA patients who are refractory to multiple biologic and targeted synthetic disease-modifying anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ochi, Sae, Sonomoto, Koshiro, Nakayamada, Shingo, Tanaka, Yoshiya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886884/ https://www.ncbi.nlm.nih.gov/pubmed/35232462 http://dx.doi.org/10.1186/s13075-022-02744-7

Ejemplares similares

Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry
por: Sonomoto, Koshiro, et al.
Publicado: (2021)

Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry
por: Kubo, Satoshi, et al.
Publicado: (2023)

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
por: Tanaka, Yoshiya, et al.
Publicado: (2022)

AJAK inhibitor, tofacitinibreduces IL-6 and matrix metalloproteinase-3 productionin rheumatoid arthritis with suppressed cartilage destruction
por: Yamaoka, Kunihiro, et al.
Publicado: (2012)

Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study
por: Miyagawa, Ippei, et al.
Publicado: (2022)

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
por: Kubo, Satoshi, et al.
Publicado: (2018)

Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

Changes in the cholesterol profile of patients with rheumatoid arthritis treated with biologics or Janus kinase inhibitors
por: Koh, Jung Hee, et al.
Publicado: (2023)

Spontaneous Differentiation of Human Mesenchymal Stem Cells on Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold
por: Sonomoto, Koshiro, et al.
Publicado: (2016)

Enhancer RNA commits osteogenesis via microRNA-3129 expression in human bone marrow-derived mesenchymal stem cells
por: Nguyen, Anh Phuong, et al.
Publicado: (2022)

Epstein–Barr virus-induced gene 3 commits human mesenchymal stem cells to differentiate into chondrocytes via endoplasmic reticulum stress sensor
por: Zhang, Tong, et al.
Publicado: (2022)

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

Role of DNA dioxygenase Ten-Eleven translocation 3 (TET3) in rheumatoid arthritis progression
por: Kawabe, Akio, et al.
Publicado: (2022)

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
por: Yamanaka, Hisashi, et al.
Publicado: (2016)

A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
por: Tanaka, Yoshiya
Publicado: (2023)

Small GTP-binding protein Rho-mediated signaling promotes proliferation of rheumatoid synovial fibroblasts
por: Nakayamada, Shingo, et al.
Publicado: (2005)

Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis
por: Miyazaki, Yusuke, et al.
Publicado: (2018)

Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
por: Ochi, Sae, et al.
Publicado: (2020)

Rheumatoid arthritis
por: Tanaka, Yoshiya
Publicado: (2020)

EULAR definition of difficult-to-treat rheumatoid arthritis
por: Nagy, György, et al.
Publicado: (2021)

IL-6 production through repression of UBASH3A gene via epigenetic dysregulation of super-enhancer in CD4(+) T cells in rheumatoid arthritis
por: Yamagata, Kaoru, et al.
Publicado: (2022)

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
por: Milici, Anthony J, et al.
Publicado: (2008)

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
por: Kotyla, Przemysław J., et al.
Publicado: (2020)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2023)

Correction: IL-6 production through repression of UBASH3A gene via epigenetic dysregulation of super-enhancer in CD4+ T cells in rheumatoid arthritis
por: Yamagata, Kaoru, et al.
Publicado: (2022)

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases
por: Nakayamada, Shingo, et al.
Publicado: (2016)

Immune Phenotype as a Biomarker for Systemic Lupus Erythematosus
por: Nakayamada, Shingo, et al.
Publicado: (2023)

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
por: Tanaka, Yoshiya, et al.
Publicado: (2015)

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study
por: Kubo, Satoshi, et al.
Publicado: (2023)

Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry
por: Kawabe, Akio, et al.
Publicado: (2020)

Novel Potential Janus Kinase Inhibitors with Therapeutic Prospects in Rheumatoid Arthritis Addressed by In Silico Studies
por: Radu, Andrei-Flavius, et al.
Publicado: (2023)

Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
por: Ebina, Kosuke, et al.
Publicado: (2023)

Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia
por: Temmoku, Jumpei, et al.
Publicado: (2023)

Non-pharmacological treatment in difficult-to-treat rheumatoid arthritis
por: Majnik, Judit, et al.
Publicado: (2022)

Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Association between Hematological Indicesand Disease Activity in Patients with Rheumatoid Arthritis Treated with Janus Kinase Inhibitors for 24 Weeks
por: Choe, Jung-Yoon, et al.
Publicado: (2022)

Are interferon-gamma release assays reliable to detect tuberculosis infection in patients with rheumatoid arthritis treated with Janus kinase inhibitors?
por: Scrivo, Rossana, et al.
Publicado: (2022)

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
por: Curtis, Jeffrey R, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p88dm68oqh9mbscidhj3767acj